Last reviewed · How we verify

NCT05553275

Permissive Intrapartum Glucose Control

Completed NA Last updated 14 May 2024
What this trial tests

NA trial testing Usual Care in Gestational Diabetes in 96 participants. Completed in 13 August 2023.

Timeline
5 October 2022
Primary endpoint
2 July 2023
13 August 2023

Quick facts

Lead sponsorThe University of Texas Health Science Center, Houston
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment96
Start date5 October 2022
Primary completion2 July 2023
Estimated completion13 August 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

The University of Texas Health Science Center, Houston

Who can join

18 and older, female only, with Gestational Diabetes or Pregestational Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess whether permissive intrapartum glycemic control compared to usual care would lead to similar rate of neonatal hypoglycemia among people with diabetes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Usual Care

Trials testing the same drug.

Other recruiting trials for Gestational Diabetes

Currently open trials in the same condition.

Other The University of Texas Health Science Center, Houston trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05553275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing